Erschienen in:

23.06.2018 | Correction

Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study

verfasst von: Alexander Egle, Michael Steurer, Thomas Melchardt, Lukas Weiss, Franz Josef Gassner, Nadja Zaborsky, Roland Geisberger, Kemal Catakovic, Tanja Nicole Hartmann, Lisa Pleyer, Daniela Voskova, Josef Thaler, Alois Lang, Michael Girschikofsky, Andreas Petzer, Richard Greil

Erschienen in: Annals of Hematology | Ausgabe 9/2018